Ticker,Title,Link
CUE,Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference,9/3/2024 2:00:00 PM
CUE,"Analysts’ Top Healthcare Picks: EKSO BIONICS (EKSO), Aziyo Biologics (ELUT)",8/20/2024 1:00:28 PM
CUE,Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights,8/19/2024 10:05:00 PM
CUE,Here's what Wall Street expects from Cue Biopharma's earnings,8/18/2024 3:01:13 PM
CUE,"CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q2 2024",8/15/2024 1:54:03 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,8/13/2024 2:00:00 PM
CUE,Stifel Nicolaus Sticks to Their Buy Rating for Cue Biopharma (CUE),7/29/2024 10:05:23 AM
CUE,"Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Tenaya Therapeutics (TNYA) and Cue Biopharma (CUE)",7/26/2024 11:01:42 AM
CUE,Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements,7/25/2024 10:05:00 PM
CUE,"Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Pharvaris (PHVS) and Cue Biopharma (CUE)",6/6/2024 5:31:14 AM
CUE,Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting,6/4/2024 2:00:00 PM
CUE,Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024,6/3/2024 2:00:00 PM
CUE,Medical Moonshots: 3 Biotech Stocks Set to Skyrocket,5/30/2024 7:30:29 PM
CUE,Cue Biopharma’s Promising Future: A Comprehensive Buy Rating Justification,5/16/2024 4:25:34 AM
CUE,Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE),5/10/2024 11:57:42 AM
CUE,Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights,5/9/2024 10:05:00 PM
CUE,Cue Biopharma to Present at the 20th Annual PEGS Boston Summit,5/8/2024 2:00:00 PM
CUE,Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference,5/7/2024 2:00:00 PM
CUE,Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting,4/24/2024 4:01:00 PM
CUE,Forecasting The Future: 4 Analyst Projections For Cue Biopharma,4/9/2024 4:01:21 PM
CUE,Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights,4/8/2024 10:05:00 PM
CUE,Notable earnings after Monday's close,4/7/2024 9:35:23 PM
CUE,Piper Sandler Remains a Buy on Cue Biopharma (CUE),4/3/2024 11:06:11 AM
CUE,"CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023",4/2/2024 5:53:00 PM
CUE,"Jefferies starts Cue at buy, cites partnering potential",3/13/2024 6:55:38 PM
CUE,"Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium",2/29/2024 4:00:00 PM
CUE,"Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)",2/26/2024 1:10:22 PM
CUE,Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference,2/6/2024 2:00:00 PM
CUE,"CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023",12/14/2023 12:04:38 PM
CUE,Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit,11/22/2023 2:00:00 PM
CUE,"Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Cue Biopharma (CUE)",11/13/2023 7:10:53 PM
CUE,Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights,11/9/2023 10:05:00 PM
CUE,Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November,11/7/2023 2:00:00 PM
CUE,"Analysts Offer Insights on Healthcare Companies: Cue Biopharma (CUE), Zoetis (ZTS) and CymaBay Therapeutics (CBAY)",11/6/2023 12:51:23 PM
CUE,Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023,11/3/2023 5:00:00 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,11/2/2023 1:00:00 PM
CUE,Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting,9/27/2023 3:05:00 PM
CUE,Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®,9/26/2023 2:00:00 PM
CUE,Cue Biopharma (CUE) Gets a Buy from Piper Sandler,8/10/2023 1:16:03 PM
CUE,"Cue Biopharma GAAP EPS of -$0.29 beats by $0.01, revenue of $1.38M beats by $0.47M",8/9/2023 8:50:27 PM
CUE,"SPWR, SOS and NCTY are among pre market gainers",7/12/2023 12:24:50 PM
CUE,3 Biotech Stocks to Buy as Companies Ink Major Deals,6/22/2023 10:40:45 AM
CUE,Where Cue Biopharma Stands With Analysts,6/15/2023 11:01:01 PM
CUE,"Analysts Are Bullish on Top Healthcare Stocks: Cue Biopharma (CUE), Agenus (AGEN)",6/7/2023 2:50:22 PM
CUE,Piper Sandler Sticks to Its Buy Rating for Cue Biopharma (CUE),6/6/2023 12:05:29 PM
CUE,3 Biotech Stocks Sitting on Huge-Upside Catalysts,5/26/2023 10:19:56 AM
CUE,"Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference",5/19/2023 7:00:19 PM
CUE,JMP Securities Sticks to Their Buy Rating for Cue Biopharma (CUE),5/15/2023 4:25:07 AM
CUE,"Analysts Offer Insights on Healthcare Companies: Supernus Pharmaceuticals (SUPN), Cue Biopharma (CUE) and Guardant Health (GH)",5/10/2023 11:30:23 AM
CUE,"Cue Biopharma GAAP EPS of -$0.29 in-line, revenue of $0.19M misses by $1.76M",5/9/2023 10:01:56 PM
CUE,7 Hot Growth Stocks Poised to Triple in 2023,5/5/2023 6:24:36 PM
CUE,7 High-Potential Penny Stocks in the Biotech Sector,5/4/2023 5:56:05 PM
CUE,2 “Strong Buy” Penny Stocks With Over 200% Upside on the Horizon,3/28/2023 2:45:05 PM
CUE,"Analysts’ Top Healthcare Picks: Cue Biopharma (CUE), Establishment Labs Holdings (ESTA)",3/23/2023 3:10:36 PM
CUE,JMP Securities Remains a Buy on Cue Biopharma (CUE),3/22/2023 5:25:09 PM
CUE,"Cue Biopharma GAAP EPS of -$0.37 misses by $0.06, revenue of $0.15M beats by $0.05M",3/21/2023 8:28:48 PM
CUE,"Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GSK), Teladoc (TDOC) and Cue Biopharma (CUE)",2/23/2023 1:20:25 PM
CUE,Cue biopharma names Matteo Levisetti as new Chief Medical Officer,1/23/2023 1:18:37 PM
CUE,Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences,11/22/2022 2:00:00 PM
CUE,JMP Securities Reaffirms Their Buy Rating on Cue Biopharma (CUE),11/21/2022 2:55:06 PM
CUE,"Cue Biopharma GAAP EPS of -$0.31 beats by $0.07, revenue of $0.07M misses by $0.37M",11/14/2022 10:35:53 PM
CUE,VC firm MDB Capital Holdings files for $10M IPO,11/11/2022 10:29:17 PM
CUE,Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of...,11/10/2022 3:00:00 PM
CUE,Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November,11/9/2022 2:00:00 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,11/7/2022 2:00:00 PM
CUE,Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket,10/24/2022 12:28:57 PM
CUE,Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting,10/5/2022 2:00:00 PM
CUE,"Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session",10/4/2022 6:41:38 PM
CUE,Cue Biopharma to Present at Two September 2022 Scientific Conferences,9/7/2022 2:00:00 PM
CUE,"Bright Minds, Minerva top healthcare gainers; Reviva, Neptune lead losers' pack",8/24/2022 2:00:17 PM
CUE,Recap Of Monday's Biotech Catalysts - End Of the Day Summary,8/23/2022 1:10:36 AM
CUE,Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers,8/22/2022 2:00:00 PM
CUE,Cue Biopharma Reports Second Quarter 2022 Financial Results,8/4/2022 10:30:00 PM
CUE,Cue Biopharma to Present at the Guggenheim I&I Spotlight Series,7/11/2022 2:00:00 PM
CUE,Cue Biopharma to Present at the JMP Securities Life Sciences Conference,6/13/2022 2:00:00 PM
CUE,Cue Biopharma to Present at the Jefferies Healthcare Conference,6/1/2022 2:00:00 PM
CUE,Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,5/26/2022 11:00:00 PM
CUE,"Elevation Oncology, Cue Biopharma top healthcare gainers, Verrica, PMV lead losers' pack",5/25/2022 2:04:40 PM
CUE,Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers,5/11/2022 2:00:00 PM
CUE,Cue Biopharma Reports First Quarter 2022 Financial Results,5/10/2022 10:30:00 PM
CUE,Cue Biopharma extends gains on insider purchase,4/5/2022 3:35:38 PM
CUE,Cue Biopharma earnings preview: what Wall Street is expecting,3/27/2022 3:01:13 PM
CUE,64 Biggest Movers From Yesterday,3/18/2022 10:23:29 AM
CUE,Cue Biopharma to Present at the Upcoming Oppenheimer 32nd Annual Healthcare Conference,3/10/2022 2:00:00 PM
CUE,"Catalyst watch for next week: GE Investor Day, Apple event and AT&T spotlight",3/4/2022 8:00:51 PM
CUE,Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress,3/2/2022 2:00:00 PM
CUE,Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting,2/15/2022 2:00:00 PM
CUE,52 Biggest Movers From Friday,1/31/2022 11:03:54 AM
CUE,33 Stocks Moving In Friday's Mid-Day Session,1/28/2022 6:07:02 PM
CUE,46 Stocks Moving In Thursday's Mid-Day Session,1/27/2022 6:11:12 PM
CUE,Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line...,1/26/2022 10:01:00 PM
CUE,"Catalyst watch for next week: Earnings blitz headlined by Apple, Microsoft, Boeing and Tesla",1/21/2022 8:00:18 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials,1/20/2022 2:00:00 PM
CUE,Cue Biopharma to get $3M from LG Chem as it reaches milestone in cancer drug program,1/5/2022 2:38:50 PM
CUE,"COVID roundup: More mandates, halving quarantine, FDA pill approval?",12/22/2021 9:08:01 AM
CUE,"As COVID cases and testing rises, test makers are mixed",12/21/2021 4:26:35 PM
CUE,"NYC to distribute 500K at-home COVID tests, 1M face masks to fight Omicron",12/16/2021 7:33:48 PM
CUE,Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer,12/15/2021 2:00:00 PM
CUE,Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit,12/6/2021 2:00:00 PM
CUE,Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference,11/22/2021 2:00:00 PM
CUE,Cue Biopharma rises on data for CUE-101 in head and neck cancer,11/15/2021 2:10:49 PM
CUE,Cue Biopharma Presents Updated Data from Lead Program CUE-101 for the Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at the Society for Immunotherapy...,11/12/2021 2:00:00 PM
CUE,Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November,11/10/2021 2:00:00 PM
CUE,Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases,10/21/2021 6:00:00 PM
CUE,Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting,10/4/2021 2:00:00 PM
CUE,"Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT",9/28/2021 2:00:00 PM
CUE,Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101,9/21/2021 2:00:00 PM
CUE,Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences,9/9/2021 2:00:00 PM
CUE,"The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline",8/18/2021 1:37:56 PM
CUE,"Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights",8/17/2021 10:01:00 PM
CUE,Here's what Wall Street expects from Cue Biopharma's earnings,8/15/2021 3:01:29 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,8/10/2021 2:00:00 PM
CUE,Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference,8/3/2021 2:00:00 PM
CUE,"The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study",7/16/2021 1:37:29 PM
CUE,"The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs",7/15/2021 2:07:56 PM
CUE,"The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues",7/14/2021 1:48:12 PM
CUE,Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference,6/14/2021 2:00:00 PM
CUE,Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC,6/10/2021 2:00:00 PM
CUE,Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting,6/3/2021 2:30:00 PM
CUE,Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference,5/26/2021 2:00:00 PM
CUE,"Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights",5/17/2021 10:01:00 PM
CUE,64 Biggest Movers From Yesterday,5/11/2021 11:03:08 AM
CUE,Mid-Afternoon Market Update: Dow Surges 125 Points; Trade Desk Shares Plunge,5/10/2021 8:39:57 PM
CUE,"The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs",5/7/2021 1:40:08 PM
CUE,Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference,5/6/2021 2:00:00 PM
CUE,Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results  and Recent Business Highlights,3/16/2021 9:01:00 PM
CUE,Cue Biopharma Inc Registered Shs hosts conference call for investors,3/15/2021 2:55:07 PM
CUE,Cue Biopharma earnings preview: what Wall Street is expecting,3/14/2021 3:01:23 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,3/9/2021 2:00:00 PM
CUE,"GME, BNGO, XSPA and WPG among premarket gainers",3/8/2021 1:19:09 PM
CUE,Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference,3/1/2021 2:00:00 PM
CUE,Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos,2/25/2021 2:00:00 PM
CUE,Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference,2/22/2021 2:00:00 PM
CUE,"Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development",2/17/2021 2:00:00 PM
CUE,Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer,2/8/2021 2:00:00 PM
CUE,7 Stocks With Insider Buying This Week Worth A Look,1/29/2021 8:34:53 PM
CUE,Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference,11/23/2020 2:00:00 PM
CUE,Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck,11/19/2020 2:00:00 PM
CUE,"Cue Biopharma reports Q3 results, issues update to lead program",11/18/2020 5:22:17 PM
CUE,Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates,11/17/2020 10:01:00 PM
CUE,Cue Biopharma to Present at Upcoming Investor Conferences in November 2020,11/11/2020 2:00:00 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,11/10/2020 2:00:00 PM
CUE,"Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the...",11/9/2020 2:00:00 PM
CUE,"Week Ahead In Pharma: FDA Decisions, SITC Presentations, 13D SEC Filing ",11/8/2020 3:52:03 PM
CUE,Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting,10/19/2020 2:00:10 PM
CUE,Cue Biopharma Welcomes Tamar Howson to its Board of Directors,9/17/2020 2:00:10 PM
CUE,Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds ,9/15/2020 2:00:10 PM
CUE,Cue Biopharma to Present at Upcoming Investor Conferences in September 2020,9/3/2020 2:00:10 PM
CUE,Cue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates,8/31/2020 10:01:10 PM
CUE,Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit,8/24/2020 2:00:10 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,8/17/2020 2:00:10 PM
CUE,Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer,7/28/2020 2:00:10 PM
CUE,Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 Superfamily,7/8/2020 2:00:10 PM
CUE,Cue Biopharma Provides Update on Ongoing Phase 1 Trial Evaluating CUE-101 in Recurrent/Metastatic Head and Neck Cancer,6/15/2020 2:00:10 PM
CUE,Cue Biopharma to Present Corporate Overview and Pipeline Progress at Jefferies Virtual Healthcare Conference,5/28/2020 2:00:10 PM
CUE,"Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights",5/19/2020 10:01:10 PM
CUE,Cue Biopharma to Present at AACR Virtual Annual Meeting,5/18/2020 2:00:10 PM
CUE,Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University,5/14/2020 2:00:10 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,5/12/2020 2:00:10 PM
CUE,Stock Alert: Cue Biopharma Gains 5% ,4/20/2020 4:59:19 PM
CUE,Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results  and Recent Business Highlights,3/17/2020 9:05:00 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,3/10/2020 1:00:00 PM
CUE,Cue Biopharma to Present at Upcoming Investor Conferences in March 2020,2/26/2020 2:00:00 PM
CUE,Oppenheimer sees big upside for small-cap biopharma,2/25/2020 2:21:22 PM
CUE,Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit,2/19/2020 2:00:00 PM
CUE,Cue Biopharma to Present at the Biomarkers Series UK,2/12/2020 2:00:00 PM
CUE,Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies,1/21/2020 2:00:00 PM
CUE,"Healthcare Stocks That Hit New Highs (XENE, AQST, DRNA...) ",12/3/2019 12:16:40 PM
CUE,Cue Biopharma to Present at the World Vaccine & Immunotherapy Congress,12/2/2019 2:00:10 PM
CUE,Cue Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights,11/12/2019 10:00:00 PM
CUE,Cue Biopharma to Present at Upcoming Investor Conferences in November 2019,11/6/2019 2:00:00 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,11/5/2019 2:00:00 PM
CUE,Cue Biopharma Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting,10/30/2019 1:00:05 PM
CUE,Cue Biopharma to Present at the Oppenheimer Houston Oncology Summit at the University of Texas MD Anderson Cancer Center,10/15/2019 2:00:00 PM
CUE,Cue Biopharma Announces Changes to its Board of Directors,10/9/2019 10:30:00 PM
CUE,Cue Biopharma Promotes Dr. Anish Suri to President and CSO,10/7/2019 10:30:00 PM
CUE,Cue Biopharma to Present Corporate Overview and Update on Clinical Development Progress for CUE-101 at the Cantor 2019 Global Healthcare Conference,10/2/2019 2:00:00 PM
CUE,Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma,9/30/2019 2:00:00 PM
CUE,Cue Biopharma to Present Corporate Overview & Clinical Strategy for CUE-101 at Jefferies 2019 Healthcare Conference,6/3/2019 2:00:00 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,5/16/2019 2:15:00 PM
CUE,"Dr. Anish Suri, Cue Biopharma’s CSO, to Participate in Panel Discussion at Upcoming NYAS Frontiers in Cancer Immunotherapy Conference",5/9/2019 2:00:00 PM
CUE,Cue Biopharma to Present Immuno-STAT Platform Technology at PEGs Boston 2019,4/8/2019 2:00:00 PM
CUE,This basketball-shooting robot is more accurate than Steph Curry from 3-point range,4/1/2019 9:30:04 PM
CUE,Cue Biopharma to Present Corporate Overview and Update at the Oppenheimer 29th Annual Healthcare Conference,3/14/2019 1:00:00 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,3/7/2019 10:30:00 PM
CUE,"7 Top Gainers In Healthcare Sector (PTX, MYOV, DXR...) ",2/14/2019 2:40:15 AM
CUE,Cue Biopharma to Present Corporate Update at 2019 BIO CEO & Investor Conference,2/11/2019 10:30:00 PM
CUE,Cue Biopharma Announces Presentation Highlighting Immuno-STAT Platform and CUE-101 at the 2019 Keystone Symposia Conference,1/16/2019 2:00:00 PM
CUE,This Day That Year: Cue Biopharma ,1/2/2019 7:58:42 AM
CUE,Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT™ Target in Oncology,12/20/2018 2:00:00 PM
CUE,Cue Biopharma to Host Business Update Call and Webcast,11/14/2018 2:00:00 PM
CUE,Cue Biopharma Presents Foundational Data on Immuno-STAT Platform and CUE-101 at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting,11/9/2018 2:00:00 PM
CUE,Cue Biopharma Announces Strategic Collaboration with LG Chem Life Sciences for Immuno-STAT™ Biologics in Oncology,11/8/2018 2:00:00 PM
CUE,Cue Biopharma Announces Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting,10/30/2018 1:00:00 PM
CUE,"Dr. Anish Suri, Cue Biopharma’s CSO, to Present at Upcoming Precision: Lung Cancer Summit",10/24/2018 2:00:00 PM
CUE,Cue Biopharma Announces Strategic Research Collaboration with Albert Einstein College of Medicine to Further the Potential of Immuno-STAT™ Platform in Chronic Infectious Diseases,10/17/2018 2:00:00 PM
CUE,Cue Biopharma Appoints Hon. Randall R. Rader to Chair Company’s Intellectual Property Committee,10/3/2018 3:00:00 PM
CUE,Cue Biopharma to Host Investor Business Update Call and Webcast,8/14/2018 2:00:00 PM
CUE,"Cue Biopharma Adds Frank Morich, M.D., Ph.D. to Board of Directors",8/3/2018 2:00:00 PM
CUE,Cue Biopharma Appoints Bethany Mancilla as Chief Business Officer and Senior Vice PresidentMancilla Brings Broad Immunotherapy Business Development and Biopharmaceutical Industry Experience,7/24/2018 2:00:00 PM
CUE,Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck,7/12/2018 2:00:00 PM
CUE,Cue Biopharma Strengthens Board of Directors  with Addition of Fred Driscoll to Chair Audit CommitteeDriscoll Brings More Than 20 Years of Experience in Financial Management of Life Sciences Companies,6/28/2018 3:15:00 PM
CUE,Cue Biopharma to Host Investor Business Update Call and WebcastUpdate on progress of selective immune modulation platform,5/10/2018 2:00:00 PM
CUE,"BRIEF-Cue Biopharma - On April 30,Gary Schuman Resigned As Interim CFO",5/1/2018 12:04:07 AM
CUE,"Cue Biopharma Announces Appointment of Anish Suri, Ph.D. as Chief Scientific OfficerDr. Suri’s appointment to senior leadership team adds depth and expertise in immunology and translational studies",4/25/2018 2:00:00 PM
CUE,Cue Biopharma to Present at Bloomberg Biotech Innovations Conference,4/5/2018 2:00:00 PM
